A study by Professor Liu Min from the School of Public Health concluded: Accelerating vaccination is the last resort to end the new crown epidemic. New crown vaccines are effective and safe in real-world studies

Professor Liu Min from the School of Public Health of Peking University recently published the paper "Efficacy and Safety of COVID-19 Vaccines in Real-World Studies: A Systematic Review and Meta-Analysis" in Infectious Diseases Caused by Poverty
.

The study conducted a summary analysis of the research data of 58 papers and found that the preventive effect of vaccination against new coronary pneumonia exceeds 85%, and the preventive effect on severe cases is as high as 95%, and it has good safety .

Liu Min introduced that due to the emergence of mutant strains, new coronary pneumonia continues to spread around the world, and it is necessary to achieve herd immunity through vaccination to prevent further mutations of the new coronary pneumonia virus and prevent the emergence of mutations that can completely escape immune monitoring
.

Real World Study ( RWS; Real World Research, RWR), that is, collecting patient-related data (RWD) in a real-world environment, and obtaining the use value and potential benefits or risks of medical products through analysis.

Evidence (RWE), the main type of study is observational

In order to further determine the efficacy and safety of the new crown vaccine in real-world research, the study screened 4,844 researches related to this topic published before July 22, 2021 from the database, and 58 were selected for analysis after review.
Papers on the efficacy and safety of COVID-19 vaccines in real-world studies, and then aggregate data from these studies to provide a reliable evidence-based basis for the actual effects of COVID-19 vaccines
.

Figure 1 Flow chart of research literature screening

Through the analysis and research of these 58 papers, it was found that when the type of vaccine was not considered: the effectiveness of a single dose of vaccine to prevent new coronary pneumonia infection was 41% ; the effectiveness of preventing symptomatic infection was 52% ; preventing hospitalization due to new coronary pneumonia The effectiveness was 66% ; the effectiveness of preventing ICU and death due to new coronary pneumonia was 45% and 53% , respectively .

Two doses of the vaccine were 85%, 97%, 93%, 96% and 95% effective in preventing these conditions, respectively .

After further analysis of different subgroups, the researchers found that the efficacy of the whole course of vaccination against different virus variants and between different vaccines was also different
.

The effectiveness of full-course vaccination against variant infection was: Alpha, 85%; Beta, 75%; Gamma, 54%; Delta, 74%

The study also found that the incidence of adverse reactions after vaccination was low: the incidence of general adverse reactions was1.

5%; the incidence of serious adverse reactions was 4 people per 100,000 people ; the death rate after vaccination was 1 per person per 100,000 people

Liu Min said that this study shows that based on the data of global real-world research, the new crown vaccine has good safety, and can effectively reduce the death, severe disease and infection caused by the new crown
.

In the context of the global pandemic of new coronary pneumonia, coupled with the threat of mutant strains, speeding up vaccination and increasing vaccine coverage are the most important and final means to end the new coronary epidemic

(Fu Donghong from the Propaganda Department)